JP4787529B2 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP4787529B2
JP4787529B2 JP2005113726A JP2005113726A JP4787529B2 JP 4787529 B2 JP4787529 B2 JP 4787529B2 JP 2005113726 A JP2005113726 A JP 2005113726A JP 2005113726 A JP2005113726 A JP 2005113726A JP 4787529 B2 JP4787529 B2 JP 4787529B2
Authority
JP
Japan
Prior art keywords
group
substituted
halogen
unsubstituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2005113726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005330266A5 (https=
JP2005330266A (ja
Inventor
英継 壷内
博文 佐々木
英明 黒田
元宏 糸谷
武司 長谷川
佳和 原口
武志 黒田
敬之 松崎
国憲 田井
眞 小松
真 松本
博之 橋詰
辰夫 富重
祐治 清家
昌則 川▲崎▼
卓美 住田
伸 宮村
絹枝 大黒
一穂 田中
勲 竹村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP2005113726A priority Critical patent/JP4787529B2/ja
Publication of JP2005330266A publication Critical patent/JP2005330266A/ja
Publication of JP2005330266A5 publication Critical patent/JP2005330266A5/ja
Application granted granted Critical
Publication of JP4787529B2 publication Critical patent/JP4787529B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2005113726A 2004-04-09 2005-04-11 医薬組成物 Expired - Lifetime JP4787529B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005113726A JP4787529B2 (ja) 2004-04-09 2005-04-11 医薬組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2004114975 2004-04-09
JP2004114975 2004-04-09
JP2004125055 2004-04-21
JP2004125055 2004-04-21
JP2005113726A JP4787529B2 (ja) 2004-04-09 2005-04-11 医薬組成物

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2008103907A Division JP4789966B2 (ja) 2004-04-09 2008-04-11 医薬組成物
JP2011101480A Division JP5345174B2 (ja) 2004-04-09 2011-04-28 医薬組成物

Publications (3)

Publication Number Publication Date
JP2005330266A JP2005330266A (ja) 2005-12-02
JP2005330266A5 JP2005330266A5 (https=) 2008-05-29
JP4787529B2 true JP4787529B2 (ja) 2011-10-05

Family

ID=35485163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005113726A Expired - Lifetime JP4787529B2 (ja) 2004-04-09 2005-04-11 医薬組成物

Country Status (1)

Country Link
JP (1) JP4787529B2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016119706A1 (zh) * 2015-01-29 2016-08-04 南京明德新药研发股份有限公司 抗肺结核病的硝基咪唑衍生物
WO2018014863A1 (zh) * 2016-07-22 2018-01-25 南京明德新药研发股份有限公司 一种硝基咪唑类化合物的晶型、盐型及其制备方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AR070301A1 (es) * 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
ES2558152T3 (es) 2007-06-08 2016-02-02 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
AU2008258560C1 (en) 2007-06-08 2014-04-10 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
ES2536406T3 (es) 2007-06-08 2015-05-25 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
BRPI0909183A2 (pt) * 2008-03-20 2015-08-25 Forest Lab Holdings Ltd Composto, composição farmacêutica e método de tratamento de condição que responde a inibidor de estearoil-coa dessaturase
CA2712613C (en) * 2008-03-26 2017-02-28 Global Alliance For Tb Drug Development Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
ES2617619T3 (es) 2008-06-05 2017-06-19 Janssen Pharmaceutica, N.V. Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR
MX2010013876A (es) * 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
ES2530266T3 (es) 2009-07-31 2015-02-27 Global Alliance For Tb Drug Development Análogos de nitroimidazooxazina y sus usos
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US20120219500A1 (en) 2009-10-26 2012-08-30 Fujifilm Ri Pharma Co., Ltd. Diagnostic agent for infectious diseases
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
JP6532457B2 (ja) * 2013-10-04 2019-06-19 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ ６−ニトロ−２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾール及びこれらの調製方法
US9822126B1 (en) * 2014-10-21 2017-11-21 Council Of Scientific & Industrial Research Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof
JP6776226B2 (ja) * 2015-03-27 2020-10-28 大塚製薬株式会社 １−（４−ヒドロキシフェニル）−４−（４−トリフルオロメトキシフェノキシ）ピペリジン又はその塩の製造方法
CN106317072B (zh) * 2015-06-17 2020-03-17 盟科医药技术(上海)有限公司 用于分枝杆菌感染治疗的杂环化合物及其应用
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
EP3632910B1 (en) * 2017-05-26 2024-07-17 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. 3,4-dihydroquinolinones as fxr receptor agonists
WO2019128963A1 (zh) * 2017-12-26 2019-07-04 南京明德新药研发股份有限公司 抗肺结核病的硝基咪唑衍生物
CN113874341B (zh) * 2019-04-01 2024-05-31 科学与工业研究委员会 制备作为有用中间体的1，1-二烷基乙烷-1，2-二醇的衍生物的方法
CN112300192B (zh) * 2019-08-02 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物及其制备方法和用途
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116570592B (zh) * 2023-04-17 2025-01-14 首都医科大学附属北京胸科医院 Gsk1292263在制备抑制结核分枝杆菌药物中的应用
CN119059990B (zh) * 2024-11-01 2025-02-07 安徽昊帆生物有限公司 1-氨基甲酸叔丁酯哌嗪的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) * 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
TWI347946B (en) * 2002-10-11 2011-09-01 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound
JP4258630B2 (ja) * 2002-10-15 2009-04-30 大塚製薬株式会社 １位置換−４−ニトロイミダゾール化合物及びその製造法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016119706A1 (zh) * 2015-01-29 2016-08-04 南京明德新药研发股份有限公司 抗肺结核病的硝基咪唑衍生物
EP3252059A4 (en) * 2015-01-29 2018-07-11 Medshine Discovery Inc. Anti-pulmonary tuberculosis nitroimidazole derivative
RU2675622C1 (ru) * 2015-01-29 2018-12-21 Медшайн Дискавери Инк. Производное нитроимидазола против туберкулеза легких
US10227362B2 (en) 2015-01-29 2019-03-12 Medshine Discovery Inc. Anti-pulmonary tuberculosis nitroimidazole derivative
WO2018014863A1 (zh) * 2016-07-22 2018-01-25 南京明德新药研发股份有限公司 一种硝基咪唑类化合物的晶型、盐型及其制备方法

Also Published As

Publication number Publication date
JP2005330266A (ja) 2005-12-02

Similar Documents

Publication Publication Date Title
JP4787529B2 (ja) 医薬組成物
JP4186065B2 (ja) ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
RU2365593C2 (ru) ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-6-НИТРОИМИДАЗО [2,1-b] ОКСАЗОЛА ДЛЯ ЛЕЧЕНИЯ ТУБЕРКУЛЕЗА
US8158620B2 (en) Fused aminodihydrothiazine derivatives
JP5345174B2 (ja) 医薬組成物
JP4761756B2 (ja) ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
HK1171018B (en) 2,3-dihydro-6-nitroimidazo (2, 1-b) oxazoles
HK1120499A (en) 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles
HK1118543A (en) 2,3-dihydro-6-nitroimidazo (2,1-b) oxazoles
HK1085463B (en) 2,3-dihydro-6-nitroimidazo (2,1-b) oxazoles
HK1181049A (en) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound
MXPA06004064A (en) 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110428

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110712

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110715

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140722

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250